Enrolled 800 Patient Articles & Analysis
24 articles found
Recent clinical trials investigating sodium-glucose cotransporter 2 inhibitors (SGLT2i) have highlighted that this drug is highly effective in treating patients with heart failure with preserved ejection fraction (HFpEF). HFpEF is a complex disease which accounts for more than half of all heart failure (HF) hospital admissions and is an increasing disease burden. [1] The prevalence of HFpEF is ...
Currently, ADC has played a significant role in the treatment of some malignant tumors, such as trastuzumab in the treatment of breast cancer, but its application in the treatment of prostate cancer (PCa) progress slowly. In recent years, ADC has made rapid progress in the treatment of metastatic castration-resistant prostate cancer (mCRPC). STEAP1, TROP2, PSMA, CD46, and B7-H3 are currently ...
With the rising demand for improving patient safety in clinical trials, the adoption of patient-centric solutions is considered the best route to enhance data accuracy and experience automated workflows. This is where eCOA comes into play. In this blog post, we will find out how electronic clinical outcome assessments are helping the clinical trials industry handle the ever-growing list of ...
ByClinion
The SIAP study investigates the effect of using Ergotrics' Inflatable Prone Support (IPS) on intra-abdominal pressure (IAP) during spine surgery. Study background The objective of this study is to demonstrate the ability of the inflatable Prone Supports (IPS) to lower the IAP of patients in the prone position. Whenever the patients’ position is changed to prone, the IAP is increased due to ...
A study conducted under the Lung Cancer Master Protocol (Lung-MAP) found that when treated with a combination of ramuzumab (Cyramza) and Keytruda, Patients with advanced NSCLC whose cancer progressed during prior immunotherapy lived significantly longer than when treated with one of the current standard therapies for this cancer. The hazard ratio (80% confidence interval) for overall survival ...
For the first time, heart failure patients can have full visibility of their hearts’ LA pressure and self-adjust their medication to stop further deterioration and avoid hospitalizations April 26, 2022 08:30 AM Eastern Daylight Time TEL AVIV, Israel–(BUSINESS WIRE)–Vectorious Medical Technologies Ltd., today announced that it has enrolled the first six patients in the ...
ABILITY Diabetes Global (Randomized Comparison of Abluminus DES+ Sirolimus-Eluting Stents versus Everolimus-Eluting Stents in Coronary Artery Disease Patients with Diabetes Mellitus Global) started off with the index patient enrolment on 11th June 2020 in Italy (at the peak of the 1st wave of COVID-19 pandemic) by P.I. Prof. Antonio Colombo and the pace of enrolment since then has been steady and ...
In the developed world, 1 in 4 people die from cancer or cancer-related disease, and cancer accounts for 13% of deaths globally. Oncology is the fastest growing therapeutic area by revenue and number of clinical trials. There’s been a huge emphasis on developing new treatments to improve survival in patients with cancer, but these trials have become a costly undertaking for sponsor ...
On February 16, 2022, the data on Paxlovid previously published by Pfizer and submitted to the FDA were published in the New England Journal of Medicine (NEJM). This NEJM article published viral load data that Paxlovid reduced viral load by 0.868 log10 compared to controls for 5 days of treatment, which equates to a remarkable 7.38-fold reduction in viral load. This pivotal study (NCT04960202) ...
Abstract Background Impaired neuromuscular control and degeneration of the multifidus muscle have been linked to the development of refractory chronic low back pain (CLBP). An implantable restorative-neurostimulator system can override the underlying multifidus inhibition by eliciting episodic, isolated contractions. The ReActiv8-B randomized, active-sham-controlled trial provided ...
Abstract Introduction. To compare the safety and efficacy of the Therapeutic Hyper-CL™ lens versus a standard bandage contact lens (PureVision B&L) for chronic corneal edema. Methods. Prospective, multicenter, randomized, crossover study. Chronic corneal edema patients were randomized to one of two arms. The first arm was fitted with the Therapeutic Hyper-CL™ lens while the ...
Abstract Almost all patients achieved sustained virological response (SVR) by direct-acting antivirals (DAA) therapy, but it is not clear as to what extent DAA therapy affects changes in liver fibrosis after achieving SVR. In this study, we investigated the changes of liver stiffness by magnetic resonance elastogaraphy (MRE) during DAA therapy. A total of 308 patients were enrolled in the study. ...
The “world’s first in-heart microcomputer” and an endovascular aortic repair (EVAR) suture-delivery catheter were recognized Saturday as the best innovations of CRT 2021 Virtual. The judges chose the V-LAP implantable microcomputer (Vectorious Medical Technologies Ltd.), presented by Tal Hasin, MD, of Shaare Zedek Medical Center, Jerusalem. CRT audience members voted for ...
February 9, 2021—Findings from the first-in-human (FIH) study assessing the safety and feasibility of the Bashir endovascular catheter (BEC; Thrombolex, Inc.) for the treatment of acute intermediate-risk pulmonary embolism (PE) were published by Akhilesh K. Sista, MD, et al in Circulation: Cardiovascular Intervention (2021;14). The BEC is a pharmacomechanical device designed to enhance ...
MOTION study will quantify new technology’s impact on radiation exposure In December, Cleveland Clinic vascular surgeons successfully completed the first surgical case in the MOTION clinical trial of a new non-radiation-based surgical navigation platform for endovascular aortic interventions. The trial is a feasibility study of the Intra-Operative Positioning System (IOPS™) from ...
PE is the most common preventable cause of death among hospital patients in the United States. VTE is a leading cause of death and disability worldwide and has the third-highest mortality rate out of any cardiovascular disease, behind myocardial infarctions and stroke. Unlike myocardial infractions and stroke, where mortality has improved considerably, VTE has seen an increase in cases, with no ...
As part of our ongoing Vascular Innovation Series in conjunction with The Way to My Heart, journalist Kym McNicholas interviewed Alucent Biomedical CEO, Dr. Myles Greenberg. Treatment for vascular blockages is getting a much-needed innovation makeover. Alucent’s first area of focus is one the most debilitating vascular diseases –peripheral artery disease, plaque build-up in mainly ...
Quick Facts LOCATION: San Diego, CA MARKET SECTOR: Hospital FACILITY SIZE: 1,030,000 square feet FACILITY PEAK LOAD: 6.8 MW EQUIPMENT: 4.6 MW Solar Turbines Mercury™ 50 gas turbine, absorption chiller FUEL: Natural Gas USE OF THERMAL ENERGY: Space and autoclave heating, absorption chilling and domestic hot water CHP TOTAL EFFICIENCY: 64% ENVIRONMENTAL BENEFITS: Less than 5ppm NOx TOTAL ...
Ancora Heart Inc., a Santa Clara, Calif.-based company looking to help those with heart failure, is heralding results from an interim analysis of patients treated in a U.S. early feasibility study evaluating the safety of the investigational Accucinch ventricular repair system. The multicenter, nonrandomized, prospective study is assessing the system in patients with symptomatic heart failure ...
It’s no secret that opioid addiction is at an all-time high and represents a major public health threat. The CDC estimates that opioid addiction resulted in a record 72,000 drug overdose deaths in 2017 alone. What strikes me as one of the most tragic parts of this narrative is that so many of these deaths were people who became addicted to opioids after simply seeking relief ...